What is the efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir (Viekira Pak) for hepatitis C virus (HCV) infection genotype 1a infection?

Updated: Oct 07, 2019
  • Author: Vinod K Dhawan, MD, FACP, FRCPC, FIDSA; Chief Editor: BS Anand, MD  more...
  • Print

HCV genotype 1a infection cure rates for the ombitasvir/paritaprevir/ritonavir and dasabuvir combination included the following:

  • No cirrhosis: SVR12 rates were 95% for 12 weeks of treatment with ribavirin (SAPPHIRE-I study) [121] ; SVR12 was 97% for 12 weeks of treatment with ribavirin but 90% without ribavirin (PEARL-IV study) [124]
  • Cirrhosis: SVR12 rates were 89% in the 12-week arm and 95% in the 24-week arm; prior treatment null responders had lower SVR rates (TURQOUISE-II study) [125]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!